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 Blood Component Usage - Per 1000 Population 
Countries Red Cells Platelets Plasma 
Australia 36.8 5.9 7.4 
Austria 50.9 4.4 8.9 
Belgium 48.4 6.4 8.1 
Canada 31.2 4.3 8.7 
Croatia 39.1 NA 15.7 
Czech Republic 39.6 3.1 19.0 
Denmark 59.8 5.9 12.6 
Estonia1 39.8 4.5 5.3 
Finland 47.0 7.5 9.4 
France1 36.3 4.2 5.3 
Germany 57.8 5.7 15.0 
Greece 55.5 11.9 19.7 
Hungary 36.1 1.4 9.4 
Iceland 42.6 6.2 14.0 
Ireland1 32.9 5.8 5.2 
Italy 41.6 3.5 8.7 
Luxembourg 41.1 4.7 8.9 
Malta1 35.0 4.1 18.0 
Netherlands 34.0 3.3 5.5 
New Zealand 28.5 3.1 4.8 
Norway 40.1 4.2 9.4 
Slovakia 34.4 5.2 14.7 
Slovenia 43.5 4.6 15.3 
Spain1 36.0 4.1 4.3 
Sweden 53.0 4.7 11.3 
Switzerland 40.8 3.8 9.1 
United Kingdom 36.2 4.5 5.1 

































































































































































































New	South	Wales 241982 7358791 32.9 256926 7262856 35.4 252792 7181410 35.2
Victoria 203374 5685931 35.8 207225 5585169 37.1 207828 5499459 37.8
Queensland 155301 4612504 33.7 166235 4522491 36.8 167051 4440761 37.6
West	Australia 64064 2478657 25.8 65742 2395701 27.4 66012 2322127 28.4
South	Australia 66311 1663431 39.9 69500 1647824 42.2 71782 1633468 43.9
Tasmania 14478 512632 28.2 15370 511794 30.0 15715 510165 30.8
Australian	Capital	Territory 12839 378335 33.9 13965 371584 37.6 13346 364875 36.6
Northern	Territory 5194 238320 21.8 6333 233586 27.1 6047 230535 26.2


















Region	1 142297.0 3650000.0 39.0 138254.0 3680000.0 37.6 136075.0 3720000.0 36.6
Region	2 43902.0 1430000.0 30.7 40175.0 1430000.0 28.1 39582.0 1440000.0 27.5
Region	3 12802.0 370000.0 34.6 13320.0 380000.0 35.1 13065.0 380000.0 34.4
Region	4 22193.0 550000.0 40.4 22510.0 560000.0 40.2 21345.0 560000.0 38.1






















Hovedstaden 119192 1636744 72.8 112118 1645825 68.1 74046 1789174 41.4
Sjaelland 53425 816116 65.5 43063 819427 52.6 31254 827499 37.8
Syddanmark 76749 1189813 64.5 73842 1194659 61.8 47702 12111770 39.4
Midtylland 70128 1227424 57.1 63613 1237041 51.4 45307 1293309 35
Nordjylland 34575 576970 59.9 35400 578839 61.2 20825 585499 35.6






Ahvenanmaa-Islands	(South-West	from	Finland) 1260 28791 43.8
South	Finland 68457 1895814 36.1
East	Finland 29775 816786 36.5
North	Finland 27677 741515 37.3
Middle	Finland 41348 1110137 37.2
West	Finland 34418 868470 39.6


















Alsace-Champagne-Ardenne-Lorraine 307493.0 5550672.0 55.4 306879.0 5554151.0 55.3 301078.0 5558160.0 54.2
Aquitaine-Limousin-Poitou-Charentes 288115.0 5826386.0 49.5 288017.0 5859024.0 49.2 273630.0 5889357.0 46.5
Auvergne-Rhones-Alpes 354944.0 7726430.0 45.9 351558.0 7768302.0 45.3 343466.0 7844798.0 43.8
Bourgogne-Franche-Comte 145954.0 2818299.0 51.8 146133.0 2820044.0 51.8 142873.0 2820673.0 50.7
Bretagne 153172.0 3247902.0 47.2 151945.0 3267551.0 46.5 149572.0 3285349.0 45.5
Centre 101623.0 2567067.0 39.6 103647.0 2573372.0 40.3 88278.0 2579285.0 34.2
Corse 15834.0 318233.0 49.8 11469.0 321865.0 35.6 10447.0 325210.0 32.1
Ile-de-France 601053.0 11929155.0 50.4 641893.0 11987311.0 53.5 583318.0 12044364.0 48.4
Languedoc-Roussillon-Midi-Pyrenees 286377.0 5655368.0 50.6 288610.0 5710759.0 50.5 282045.0 5764753.0 48.9
Nord-Pas-de-Calais-Picardie 268413.0 5980491.0 44.9 262168.0 5992338.0 43.8 260174.0 6001823.0 43.3
Normandie 150302.0 3325560.0 45.2 148342.0 3329982.0 44.5 137029.0 3333128.0 41.1
Pays	de	la	Loire 163635.0 3646733.0 44.9 161658.0 3674627.0 44.0 158420.0 3702235.0 42.8
Provences-Alpes-Cote	d	Azur 236321.0 4944626.0 47.8 235891.0 4962649.0 47.5 234679.0 4980529.0 47.1





















Valle	d'Aosta 4900.0 127844.0 38.3 4782.0 128591.0 37.2 4772.0 128298.0 37.2
Piemonte 197761.0 4374052.0 45.2 188917.0 4436798.0 42.6 187100.0 4424467.0 42.3
Liguria 73023.0 1565127.0 46.7 71000.0 1591939.0 44.6 72903.0 1583263.0 46.0
Lombardia 466480.0 9794525.0 47.6 457428.0 9973397.0 45.9 464078.0 10002615.0 46.4
PA	di	Trento 22098.0 530308.0 41.7 21314.0 536237.0 39.7 20605.0 537416.0 38.3
PA	di	Bolzano 22486.0 509626.0 44.1 21511.0 515714.0 41.7 20316.0 518518.0 39.2
Friuli	Venezia	Giulia 61398.0 1221860.0 50.2 56104.0 1229363.0 45.6 54757.0 1227122.0 44.6
Veneto 242254.0 4881756.0 49.6 239293.0 4926818.0 48.6 242527.0 4927596.0 49.2
Emilio	Romagna 230128.0 4377487.0 52.6 217981.0 4446354.0 49.0 212905.0 4450508.0 47.8
Toscana 174643.0 3692828.0 47.3 169630.0 3750511.0 45.2 164153.0 3752654.0 43.7
Umbria 43520.0 886239.0 49.1 44046.0 896742.0 49.1 44099.0 894762.0 49.3
Marche 75003.0 1545155.0 48.5 74163.0 1553138.0 47.8 74499.0 1550796.0 48.0
Lazio 218856.0 5557276.0 39.4 213323.0 5870451.0 36.3 211633.0 5892425.0 35.9
Sardegna 114478.0 1640379.0 69.8 110805.0 1663859.0 66.6 111416.0 1663286.0 67.0
Abruzzo 54206.0 1312507.0 41.3 54726.0 1333939.0 41.0 54500.0 1331574.0 40.9
Campania 156111.0 5769750.0 27.1 158710.0 5869965.0 27.0 165633.0 5861529.0 28.3
Molise 15093.0 313341.0 48.2 16329.0 314725.0 51.9 15788.0 313348.0 50.4
Puglia 153566.0 4050803.0 37.9 152600.0 4090266.0 37.3 153969.0 4090105.0 37.6
Basilicata 24008.0 576194.0 41.7 25222.0 578391.0 43.6 24185.0 576619.0 41.9
Calabria 67442.0 1958238.0 34.4 66512.0 1980533.0 33.6 68089.0 1976631.0 34.4
Sicilia 202732.0 4999932.0 40.5 200177.0 5094937.0 39.3 200423.0 5092080.0 39.4








Aargau-Solothurn 20202 886623 22.8
Basel 24996 463962 53.9
Bern 49185 992617 49.6
Fribourg 8499 291395 29.2
Geneva 22174 463101 47.9
Grisons 6617 233289 28.4
Neuchâtel-Jura 6521 245496 26.6
Eastern	Switzerland 19081 666310 28.6
Svizzera	Italiana 12174 341652 35.6
Valais 13461 321732 41.8
Vaud 31179 734356 42.5
Central	Switzerland 17910 690964 25.9
Zurich 65583 1707563 38.4









Flanders 2012 302544 6835577 44.26
Other 2012 206055 4200371 49.06
National 2012 508599 11035948 46.09
Flanders 2013 280727 6896445 40.71
Other 2013 195818 4235824 46.23
National 2013 476545 11132269 42.81
Flanders 2014 261561 6911226 37.85
Other 2014 190322 4244910 44.84
National 2014 451883 11156136 40.51
Flanders 2015 254839 6944003 36.7
Other 2015 186020 4265041 43.62





England 2012 53,493,729 32.86
Scotland 2012 5,313,600 34.9
Wales 2012 3,074,067 36.62
NI 2012 1,823,634 29.05
England 2013 53,865,800 31.63
Scotland 2013 5,327,700 33.85
Wales 2013 3,082,400 31.73
NI 2013 1,829,700 26.4
England 2014 54,316,600 30.62
Scotland 2014 5,347,600 31.55
Wales 2014 3,092,000 31.41






	Figure	3.5:	Scatterplot	showing	correlation	of	population	size	of	region	and	regional	red	cell	usage	per	1,000	population				 Red	Cell	Use	per	1000	population	Population	size	of	region	 Pearson	Correlation	 0.217	P-value	 0.004	Sample	Size	 171	Table	3.15:	Table	showing	Pearson	correlation	and	P-value	for	the	relationship	between	population	size	of	region	and	regional	red	cell	usage	per	1,000	population.		
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Aargau-Solothurn Aargau,	Solothurn 20202 27891 886623 148501 22.8 31.5
Basel Basel-Stadt,	Basel-Land yes 24996 21247 463962 95021 53.9 45.8
Bern Bern yes 49185 41807 992617 192915 49.6 42.1
Fribourg Fribourg 8499 10674 291395 42007 29.2 36.6
Geneva Geneva yes 22174 18848 463101 75727 47.9 40.7
Grisons Grisons,	Glarus 6617 8871 233289 43531 28.4 38.0
Neuchâtel-Jura Neuchâtel,	Jura 6521 8859 245496 45156 26.6 36.1
Eastern	SwitzerlandSt.	Gall	(70%),	Thurgau,	Appenzell	Inner-/Ausserrhoden 19081 24774 666310 109950 28.6 37.2
Svizzera	Italiana Ticino 12174 12174 341652 71889 35.6 35.6
Valais Valais 13461 16424 321732 57234 41.8 51.0
Vaud Vaud yes 31179 26502 734356 117744 42.5 36.1
Central	SwitzerlandLucerne,	Zug,	Obwalden,	Nidwalden,	Uri,	Schwyz	(50%) 17910 23765 690964 113091 25.9 34.4
Zurich Zurich,	Schaffhausen,	St.	Gall	(30%),	Schwyz	(50%) yes 65583 55746 1707563 285852 38.4 32.6









































1. Per	Cent	Population	above	65	years	(Organisation	for	Economic	Co-operation	and	Development,	2009b)	2. Human	Development	Index	(HDI)	(United	Nations	Development	Programme,	2011)	3. Gross	Domestic	Product	(GDP)	per	Capita	US$	(World	Bank,	2009c)	4. Health	Care	Expenditure	per	Capita	US$	Purchasing	Power	Parity	(World	Bank,	2009b)	5. Population	Density	–	Persons	per	Square	Kilometre	(Heal	The	World	Foundation,	2012)	6. Prevalence	of	Coronary	Artery	Bypass	Surgery	per	100,000	Population	(Organisation	for	Economic	Co-operation	and	Development,	2009a)	7. Prevalence	of	Hip	Replacement	Surgery	per	100,000	Population	(Organisation	for	Economic	Co-operation	and	Development,	2009a)	8. Age	Standardised	rate	per	100,000	population	for	all	cancers	excluding	non-melanoma	skin	cancers	(International	Agency	for	Research	on	Cancer,	2008)	9. Age	Standardised	rate	per	100,000	population	for	HL,	NHL,	Leukaemia	&	MM	(International	Agency	for	Research	on	Cancer,	2008)	10. Maternal	Mortality	Ratio	per	100,000	Live	Births	(World	Bank,	2009a)		Table	4.2	on	page	70	lists	the	values	for	the	key	performance	indicators	used	in	the	country	health	service	system	ranking	exercise	discussed	in	Section	4.2	(page	64).	The	individual	indicators	were	extracted	from	the	OECD	database	(Organisation	for	Economic	Co-operation	and	Development,	2016a)	and	are	listed	below.	All	indicators	relate	to	2009	or	the	nearest	year	and	all	have	the	specific	web	address	indicated,	or	their	digital	object	identifier	(DOI)	number,	for	ease	of	reference.	Indicators	1	through	to	7	were	extracted	from	the	Health	Care	Quality	Indicators	and	indicators	8	to	10	were	extracted	from	the	Cancer	Care	sub-set	of	the	Health	Care	Quality	Indicators.		
67	
1. Asthma	and	Chronic	Obstructive	Pulmonary	Disease	hospital	admissions	in	total	population	aged	15	years	and	over	-	Age-standardised	rate	per	100,000	population	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	2. Congestive	Heart	Failure	and	Hypertension	hospital	admissions	in	total	population	aged	15	years	and	over	-	Age-standardised	rate	per	100,000	population	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	3. Diabetes	hospital	admissions	in	total	population	aged	15	years	and	over	-	Age-standardised	rate	per	100,000	population	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	4. 30-day	mortality	after	hospital	admission	for	Myocardial	Infarction	in	total	population	aged	45	years	and	over	-	Age	and	sex	standardised	rate	per	100	patients	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	5. 30-day	mortality	after	hospital	admission	for	Haemorrhagic	Stroke	in	total	population	aged	45	years	and	over	-	Age	and	sex	standardised	rate	per	100	patients	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	6. 30-day	mortality	after	hospital	admission	for	Ischaemic	Stroke	in	total	population	aged	45	years	and	over	-	Age	and	sex	standardised	rate	per	100	patients	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	7. Hip	fracture	surgery	initiated	within	2	days	after	admission	to	hospital	in	total	population	aged	65	years	and	over	-	Crude	rate	per	100	patients	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	8. Breast	cancer	5-year	relative	survival	in	the	female	population	aged	15	years	and	over	-	Age	standardised	survival	-	%	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	9. Cervical	cancer	5-year	relative	survival	in	the	female	population	aged	15	years	and	over	-	Age	standardised	survival	-	%	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	
68	






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Red Cell Usage per 1000 Population – Per Cent Population 
above 65 years 
0.556 0.002 
Red Cell Usage per 1000 Population – Human 
Development Index (HDI) 	 0.128 0.517 
Red Cell Usage per 1000 Population – Gross Domestic 
Product (GDP) per Capita US$	 0.194 0.324 
Red Cell Usage per 1000 Population – Health Care 
Expenditure per Capita US$ Purchasing Power Parity	 0.308 0.110 
Red Cell Usage per 1000 Population – Population Density 
– Persons per Square Kilometre	 -0.107 0.588 
Red Cell Usage per 1000 Population – Prevalence of 
Coronary Artery Bypass Surgery per 100,000 Population	 0.483 0.014 
Red Cell Usage per 1000 Population – Prevalence of Hip 
Replacement Surgery per 100,000 Population	 0.612 0.001 
Red Cell Usage per 1000 Population – Age Standardised 
rate per 100,000 population for all cancers excluding non-
melanoma skin cancers	 -0.208 0.288 
Red Cell Usage per 1000 Population – Age Standardised 
rate per 100,000 population for HL, NHL, Leukaemia & MM	 -0.347 0.070 
Red Cell Usage per 1000 Population – Maternal Mortality 

















Platelet Usage per 1000 Population – Colorectal	cancer	5-year	relative	survival	in	the	total	population	aged	15	years	and	over	(age	standardised	survival	-	%)	 0.473 0.047 















value B Std. Error Beta 
 
(Constant) 28.979 11.047  2.623 0.017 
Per Cent population over 65 Years 1.377 0.479 0.414 2.873 0.010 
Health Care Expenditure per Capita 
US$ Purchasing Power Parity 
0.002 0.001 0.410 3.031 0.007 
Population Density - Persons per 
Square Kilometre 
-0.022 0.010 -0.292 -2.098 0.050 
Prevalence of Coronary Artery 
Bypass Surgery per 100,000 
Population 
0.151 0.040 0.515 3.755 0.001 
Age-standardised Rate per 100,000 
Population for HL, NHL, Leukaemia & 
MM 
-0.960 0.308 -0.458 -3.117 0.006 
R R Square Adjusted R Square Std. Error of the Estimate 
0.840 0.705 0.627 4.91643 
78	
Table	4.8: Coefficients for platelet usage as dependent variable 
 			Table	4.9:	Model	summary	-	platelets		The	parsimonious	regression	model	that	related	the	dependent	variable	‘Plasma	Usage	per	1000	Population’	to	the	explanatory	variables	identified	2	predictors	using	a	backward	procedure	(Table	4.10).	One	of	them	is	marginally	positively	correlated	and	the	other	is	negatively	correlated:	‘Prevalence	of	Coronary	Artery	Bypass	Surgery	per	100,000	Population’	(P-value	=	0.053);	and	‘Age-standardised	Rate	per	100,000	Population	for	HL,	NHL,	Leukaemia	&	MM’	(P-value=	0.038).	However,	this	two-	predictor	model	explained	only	24.7%	of	the	total	variance	(Table	4.11).		






t P-value B Std. Error Beta 
(Constant) 11.877 3.923  3.028 0.006 
Per Cent Pop over 65 -0.201 0.110 -0.362 -1.832 0.081 
Prev CABS per 100,000 Pop 0.026 0.009 0.527 2.743 0.012 
All Cancers exc Non-melanoma Skin 
Cancers – Age Std Rate per 
100,000 Pop 
-0.017 0.010 -0.359 -1.777 0.090 
R R Square Adjusted R Square Std. Error of the Estimate 






t P-value B Std. Error Beta 
 
(Constant) 16.357 4.447  3.678 0.001 
Prevalence of Coronary Artery 
Bypass Surgery per 100,000 
Population 
0.057 0.028 0.393 2.049 0.053 
Age Standardised rate per 100,000 
population for HL, NHL, Leukaemia 
& MM 





R R Square Adjusted R Square Std. Error of the Estimate 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.5	Conclusion		Up	to	this	point,	the	following	has	been	established:	1. There	is	significant	variation	between	the	rates	of	usage	of	blood	components	across	a	number	of	countries	though	this	does	not	correlate	with	overall	health	service	performance.	The	variation	therefore	cannot	be	explained	by	different	health	system	outcomes	but	must	be	related	to	other	reasons.	2. The	rate	at	which	blood	products	are	used,	seems	to	be	associated	with	a	number	of	predictors	which	can	contribute	to	a	portion	of	the	variation	in	blood	product	usage	across	different	countries.	These	predictors	include	a) The	percentage	of	the	country	population	that	is	over	65	years	of	age	b) The	population	density	within	the	specific	country	c) Clinical	activity	as	represented	by	CABG	and	the	burden	of	cancer	
91	





















































































































































































































































































































































































































































































































Country	 pdi	 idv	 mas	 uai	 ltowvs	 ivr	
Australia	 36	 90	 61	 51	 21	 71	
Austria	 11	 55	 79	 70	 60	 63	
Belgium	 65	 75	 54	 94	 82	 57	
Canada	 39	 80	 52	 48	 36	 68	
Czech	Republic	 57	 58	 57	 74	 70	 29	
Denmark	 18	 74	 16	 23	 35	 70	
Estonia	 40	 60	 30	 60	 82	 16	
Finland	 33	 63	 26	 59	 38	 57	
France	 68	 71	 43	 86	 63	 48	
Germany	 35	 67	 66	 65	 83	 40	
Greece	 60	 35	 57	 112	 45	 50	
Hungary	 46	 80	 88	 82	 58	 31	
Ireland	 28	 70	 68	 35	 24	 65	
Italy	 50	 76	 70	 75	 61	 30	
Luxembourg	 40	 60	 50	 70	 64	 56	
Malta	 56	 59	 47	 96	 47	 66	
Netherlands	 38	 80	 14	 53	 67	 68	
New	Zealand	 22	 79	 58	 49	 33	 75	
Norway	 31	 69	 8	 50	 35	 55	
Slovakia	 104	 52	 110	 51	 77	 28	
Slovenia	 71	 27	 19	 88	 49	 48	
Spain	 57	 51	 42	 86	 48	 44	
Sweden	 31	 71	 5	 29	 53	 78	
Switzerland	 34	 68	 70	 58	 74	 66	
United	Kingdom	 35	 89	 66	 35	 51	 69	
United	States	 40	 91	 62	 46	 26	 68	Table	5.7:	Values	for	Hofstede’s	cultural	dimensions		
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Attachment	to	correspondence		Subsequent	Council	of	Europe	documents	have	shown	that	blood	usage	across	different	countries	varies.	It	has	been	posited	that	this	variance	may	be	a	result	of	demographic	differences	rather	than	an	actual	difference	in	specific	medical	practice.	A	performance	of	statistical	correlations	does	indicate	that	this	variance	may	indeed	be	partially	explained	by	demographics.	But	not	all	of	it	is.	I	have	attempted	to	build	a	model	showing	the	association	of	the	variance	with	a	number	of	factors.	It	appears	that	as	one	would	intuitively	expect,	the	variance	is	associated	with	indices	such	as	‘Per	Cent	Population	over	65	Years’	(as	has	been	shown	in	a	couple	of	publications)	and	the	‘Prevalence	of	Coronary	Artery	Bypass	Surgery	per	100,000	Population’.	It	does	however	also	seem	likely	that	blood	use	varies	with	the	‘Health	Care	Expenditure	per	Capita	US$	Purchasing	Power	Parity’,	and	also	that	part	of	the	variance	cannot	be	explained	except	perhaps	by	real	differences	in	practice.	This	latter	point	is	also	evident	from	the	publications	showing	differences	in	practice	across	countries	and	even	across	institutions	within	the	same	country	with	regards	to	the	use	of	red	cells	in	specific	procedures	such	as	hip	replacement	and	cardiac	surgery.		Up	until	now,	I	have	used	only	National	statistics	available	from	various	public	reports	and	various	publically	available	databases.	At	this	stage	I	would	like	to	look	at	the	differences	across	regions	within	the	same	country.	I	would	like	to	examine	the	hypothesis	that	the	patterns	of	usage	are	consistent	across	the	country	(i.e.	very	similar	in	a	majority	of	regions)	as	opposed	to	the	hypothesis	that	every	region	has	a	different	pattern	of	usage	and	the	national	figure	is	only	a	composite	of	what	occurs	in	the	regions.		I	would	be	sincerely	grateful	if	you	could	help	me	out	with	this.	In	order	to	examine	the	hypothesis,	I	would	need	figures	for	red	cell	use	(or	red	cell	distribution)	in	the	regions	and,	if	available,	the	population	of	the	individual	regions.	If	possible,	the	data	should	be	for	either	of	2012,	2013	or	2014.		I	am	attaching	a	template	for	ease	of	compilation:		Country:	 XXXXXXXXXXX	(Insert	Name	of	Country)		 Region	Name	 Red	Cells	Used	Within	Region	2012	/	2013	/	2014	(Circle	as	appropriate)	
Population	of	Region	
Region	1	 	 	 	Region	2	 	 	 	Region	3	 	 	 	Region	4	 	 	 	Region	5	 	 	 	Etc…	 	 	 		
